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Inspiring Compassion for Rare Diseases
Colton Margus
When I was asked to contribute to this volume of Quill & 
Scope, I was thrilled to have the opportunity to introduce Stu-
dent Advocates for Neglected Diseases (STAND), the new 
student group that I started here at New York Medical Col-
lege to spur greater student engagement with this small and 
most in-need patient community.
Despite what we learn in the classroom, many medical stu-
dents across the country are not su"ciently exposed to and 
thus not fully appreciative of the deeper burdens that patients 
and families with rare and neglected diseases face. I want 
STAND to address that, because I believe doing so will lead to 
more informed and compassionate physicians.
Rare diseases are o%en life-threatening or chronically debili-
tating, and each rare disease a&ects a very small portion of the 
population (fewer than 200,000 people in the United States).1 
Neglected or orphan diseases include both rare inherited dis-
orders as well as neglected infectious diseases a&ecting the 
global poor. Such diseases are traditionally not given a high 
priority for prevention or treatment and, as a result, lack suf-
#cient attention from governments, healthcare professionals, 
news media, and drug developers.
!e Orphan Drug Act of 1983 and the subsequent Rare Dis-
eases Act of 2002 exemplify laudable e&orts to “promote the 
development of drugs and devices for rare diseases” through 
establishing a national o"ce, increasing research funding, 
and improving incentives for development of new thera-
pies.1 However, the complexities of rare and neglected dis-
ease diagnosis at the level of individual patients and families 
are still underappreciated within the medical profession. 
 
At the heart of the matter is the belief that all patients should 
matter. Neglected conditions have a harder time attracting 
funding and support, and patients o%en su&er from that 
oversight. Tens of millions of Americans are a&ected by near-
ly seven thousand rare diseases, most of which lack any treat-
ment or cure. !eir need for a helping hand does not depend 
on disease prevalence—and neither should our compassion. 
 
What should be great news for busy medical professionals 
and students is that the smallest e&ort for the smallest com-
munities can o%en make the biggest di&erence. Having an 
impact on a rare disease does not necessarily mean #nding a 
cure. Coping with a rare disease can be incredibly isolating, 
and an outstretched hand from the medical community can 
mean the world. Just spending one-to-one time with the pa-
tients and their families and showing genuine interest in what 
life is like for them can provide tremendous encouragement. 
It can alleviate their feelings of being forgotten and provide 
encouragement that the next generation of physicians will be 
sensitive to their needs. 
Even beyond the orphan communities themselves, progress 
on behalf of neglected diseases helps to advance the medi-
cal #eld more broadly. A substantial part of today’s medical 
knowledge originated in the pursuit of an overlooked ques-
tion or with a rare disease model.2 Future physicians must ap-
preciate that neglected diseases can o&er fertile opportunities 
to advance innovative new research strategies and treatment 
methods for more common disorders. In fact, as healthcare 
management shi%s toward personalized medicine targeting 
smaller and smaller subsets of the general population,3 one 
could argue that our research models developed on behalf of 
rare disease communities will be all the more relevant.
I am admittedly biased—two of my younger brothers su&er 
from a rare genetic disease called ataxia telangiectasia (A-
T). At a birth frequency of 1 in 300,000, my brothers’ auto-
somal recessive truncation of the ataxia telangiectasia mu-
tated (ATM) gene is extremely rare, but no less devastating 
in its stunted growth, progeric aging, cancer predisposition, 
immune de#ciency, and cerebellar degeneration.4 On top of 
coping with their sons’ diminishing quality of life, my parents 
have had to #ght indi&erent insurance companies and navi-
gate enormous bureaucracies for support. I have seen doctors 
misdiagnose and misguide treatment, but I have also seen 
wonderful physicians listen carefully to my family’s concerns 
and recognize the importance of collaborating with patients 
and their families in managing a disease. I have seen the enor-
mous di&erence a good physician can make to families like 
mine, even when there is no cure.
Now that I am in medical school myself, I want to take the 
opportunity to convince receptive future doctors of the value 
in championing and understanding rare diseases just as they 
begin their careers. I hope to plant the seed in the next gener-
ation of healthcare professionals by getting medical students 
to think about and to engage with patient communities that 
they might never come across otherwise.
STAND is busy organizing several events on campus to bring 
attention to rare disease patients and their families. For ex-
ample, following our introduction to the DNA-repair dis-
order xeroderma  pigmentosum (XP) in our biochemistry 
course last spring, we invited Caren Mahar, patient mother 
and founder of the XP Society and Camp Sundown, to vis-
it New York Medical College. It was a great opportunity for 
students to hear a more personal perspective on the disorder, 
and to better understand the o%en overlooked burdens on 
families diagnosed with incurable diseases they cannot even 
pronounce.
Still, as much as lectures and presentations raise awareness, 
nothing compares to the e&ect that direct, individually-driv-
en interactions can have on one’s outlook, investment, and 
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propensity for future engagement. !at is why STAND is 
brainstorming more creative ways to get the student body di-
rectly involved with patients, both on campus and at other 
medical institutions.
Our newly created “David R. Cox Prize for Rare Compassion” 
will recognize the essays of student doctors who have most 
inspiringly engaged a rare or neglected patient community 
that they have encountered.  Participating students will meet 
with an unfamiliar patient, family, or advocate a&ected by a 
rare disease, and share their newfound insights a%erwards in 
a short essay.  Beyond that, it is also my hope that with help 
from the Global Genes Project, an international organization, 
we will be able to facilitate Rare Disease Day activities at med-
ical schools around the country.  !ere are a lot of exciting 
directions we can go in.
!roughout this process, it has been overwhelming to see 
how many people have come out of the woodwork for some-
thing meaningful. Even in the group’s infancy, we have al-
ready garnered the support of students, administrators, and 
faculty alike, and their collective response has been more than 
I could have hoped for.
I feel incredibly fortunate and look forward to seeing the inte-
gration of our classroom foundations with rare disease advo-
cacy and patient engagement. I am optimistic that our doing 
so will make a positive di&erence in our community and in 
how at least one doctor approaches patients and their families 
somewhere down the road.
Author’s note: Associate Dean Tony Sozzo’s support has been 
invaluable in the success of this student group, and a meeting 
in January 2014 organized by Dr. Jennifer Koestler reiterated 
the school’s commitment not only to supporting student initia-
tives but also to adapting the New York Medical College curric-
ulum and learning experience in a way that will produce even 
better doctors. 
REFERENCES 
1. U.S. Government Printing O"ce. Rare Dis-
eases Act of 2002. November 6, 2002. http://
www.gpo.gov/fdsys/pkg/PLAW-107publ280/html/PLAW-
107publ280.htm. Accessed February 4, 2014.
2. European Organization for Rare Diseases (EURORDIS). 
Position Paper: Why Research on Rare Diseases? October 
2010. http://download.eurordis.org/documents/pdf/why_
rare_disease_research.pdf. Accessed February 4, 2014. 
3. U.S. Food and Drug Administration (FDA). Paving the 
Way for Personalized Medicine: FDA’s Role in a New Era of 
Medical Product Development. October 2013. http://www.
fda.gov/downloads/scienceresearch/specialtopics/personal-
izedmedicine/ucm372421.pdf. Accessed February 4, 2014.
4. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangi-
ectasia. J Clin Pathol. 2005 Oct;58(10):1009-15.
